S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Biden's Plan to Confiscate Your Cash? (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Biden's Plan to Confiscate Your Cash? (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Biden's Plan to Confiscate Your Cash? (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Biden's Plan to Confiscate Your Cash? (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Biden's Plan to Confiscate Your Cash? (Ad)
NASDAQ:NEO

NeoGenomics - NEO Stock Forecast, Price & News

$12.91
+0.29 (+2.30%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$12.46
$12.98
50-Day Range
$7.06
$12.91
52-Week Range
$6.85
$54.74
Volume
1.73 million shs
Average Volume
1.96 million shs
Market Capitalization
$1.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.54

NeoGenomics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
51.9% Upside
$19.62 Price Target
Short Interest
Healthy
4.63% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.34mentions of NeoGenomics in the last 14 days
Based on 17 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.04) to ($0.78) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

733rd out of 1,125 stocks

Testing Laboratories Industry

1st out of 1 stocks

NEO stock logo

About NeoGenomics (NASDAQ:NEO) Stock

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on NEO. StockNews.com raised NeoGenomics to a "sell" rating in a research note on Saturday. The Goldman Sachs Group boosted their price objective on NeoGenomics from $18.00 to $20.00 and gave the stock a "buy" rating in a research note on Wednesday, August 10th. Needham & Company LLC reduced their target price on NeoGenomics from $19.00 to $16.00 and set a "buy" rating on the stock in a research report on Wednesday, August 10th. Piper Sandler started coverage on NeoGenomics in a research report on Thursday, June 2nd. They issued an "overweight" rating and a $13.00 target price on the stock. Finally, Morgan Stanley reduced their target price on NeoGenomics from $19.00 to $18.00 and set an "equal weight" rating on the stock in a research report on Wednesday, August 10th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $19.54.

NeoGenomics Trading Up 1.7 %

Shares of NEO Stock traded up $0.22 on Monday, hitting $12.84. The stock had a trading volume of 60,115 shares, compared to its average volume of 1,945,383. The company has a debt-to-equity ratio of 0.51, a current ratio of 7.53 and a quick ratio of 7.26. The firm has a market capitalization of $1.62 billion, a P/E ratio of -10.64 and a beta of 0.94. NeoGenomics has a 1 year low of $6.85 and a 1 year high of $54.74. The company's 50 day moving average price is $9.00 and its 200-day moving average price is $12.66.

NeoGenomics (NASDAQ:NEO - Get Rating) last posted its quarterly earnings data on Tuesday, August 9th. The medical research company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.06. The firm had revenue of $125.00 million for the quarter, compared to the consensus estimate of $123.26 million. NeoGenomics had a negative return on equity of 8.53% and a negative net margin of 30.00%. The company's quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.04) EPS. Analysts anticipate that NeoGenomics will post -1.04 earnings per share for the current year.

Receive NEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.

NEO Stock News Headlines

NeoGenomics (NASDAQ:NEO) Upgraded at StockNews.com
NeoGenomics (NASDAQ:NEO) PT Lowered to $18.00 at Morgan Stanley
NeoGenomics (NASDAQ:NEO) Price Target Cut to $16.00
NeoGenomics: Q2 Earnings Insights - Benzinga
NeoGenomics (NEO) to Release Earnings on Tuesday
StockNews.com Upgrades NeoGenomics (NASDAQ:NEO) to Sell
NEO (NEO) Definition
Is it Still Worthy to Invest in NeoGenomics (NEO)?
See More Headlines
Receive NEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.

NEO Company Calendar

Last Earnings
8/09/2022
Today
8/16/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Testing laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NEO
Employees
2,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.62
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+51.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

Net Income
$-8,350,000.00
Pretax Margin
-33.02%

Debt

Sales & Book Value

Annual Sales
$484.33 million
Cash Flow
$0.19 per share
Book Value
$9.00 per share

Miscellaneous

Free Float
124,538,000
Market Cap
$1.62 billion
Optionable
Optionable
Beta
0.94

Key Executives














NEO Stock - Frequently Asked Questions

Should I buy or sell NeoGenomics stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NEO shares.
View NEO analyst ratings
or view top-rated stocks.

What is NeoGenomics' stock price forecast for 2022?

11 analysts have issued 1-year price objectives for NeoGenomics' stock. Their NEO share price forecasts range from $13.00 to $30.00. On average, they predict the company's stock price to reach $19.54 in the next year. This suggests a possible upside of 52.3% from the stock's current price.
View analysts price targets for NEO
or view top-rated stocks among Wall Street analysts.

How have NEO shares performed in 2022?

NeoGenomics' stock was trading at $34.12 at the start of the year. Since then, NEO shares have decreased by 62.4% and is now trading at $12.83.
View the best growth stocks for 2022 here
.

When is NeoGenomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our NEO earnings forecast
.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) released its quarterly earnings data on Tuesday, August, 9th. The medical research company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.06. The medical research company earned $125 million during the quarter, compared to analyst estimates of $123.26 million. NeoGenomics had a negative net margin of 30.00% and a negative trailing twelve-month return on equity of 8.53%. The business's revenue for the quarter was up 2.5% on a year-over-year basis. During the same period in the prior year, the business earned ($0.04) earnings per share.

What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?

116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Brown Advisory Inc. (4.46%), Assenagon Asset Management S.A. (2.89%), First Light Asset Management LLC (2.18%), Northern Trust Corp (1.01%), Emerald Advisers LLC (0.97%) and Principal Financial Group Inc. (0.63%). Insiders that own company stock include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Mark Mallon, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends
.

How do I buy shares of NeoGenomics?

Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeoGenomics' stock price today?

One share of NEO stock can currently be purchased for approximately $12.83.

How much money does NeoGenomics make?

NeoGenomics (NASDAQ:NEO) has a market capitalization of $1.61 billion and generates $484.33 million in revenue each year. The medical research company earns $-8,350,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis.

How many employees does NeoGenomics have?

The company employs 2,000 workers across the globe.

How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The official website for the company is www.neogenomics.com. The medical research company can be reached via phone at (239) 768-0600, via email at sjones@neogenomics.com, or via fax at 239-690-4237.

This page (NASDAQ:NEO) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.